{
  "resourceType": "Research",
  "title": "Efficacy",
  "name": "M11",
  "status": "active",
  "meta": {
    "versionId": "98",
    "lastUpdated": "2025",
    "profile": [
      "http://hl7.org/fhir/research-study-prim-purp-type"
    ]
  },
  "period": {
    "start": "2015",
    "end": "2017"
  },
  "primaryPurposeType": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/research-study-prim-purp-type",
        "code": "treatment",
        "display": "Treatment"
      }
    ]
  },
  "recruitment": {
    "targetNumber": 302,
    "actualNumber": 321,
    "eligibility": {
      "reference": "Group/347729",
      "type": "Group",
      "display": "Eligibility"
    }
  },
  "phase": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/research-study-phase",
        "code": "3",
        "display": "3"
      }
    ]
  },
  "label": [
    {
      "type": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/title-type",
            "code": "acronym",
            "display": "Acronym"
          }
        ]
      },
      "value": "DERIVE"
    }
  ],
  "identifier": [
    {
      "use": "official",
      "value": "NCT",
      "assigner": {
        "display": "https://clinicaltrials.gov/"
      }
    }
  ],
  "progressStatus": [
    {
      "state": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/research-study-status",
            "code": "completed",
            "display": "Completed"
          }
        ]
      }
    }
  ],
  "condition": [
    {
      "text": "Type"
    },
    {
      "text": "Moderate"
    }
  ],
  "region": [
    {
      "text": "88"
    }
  ],
  "studyDesign": [
    {
      "coding": [
        {
          "system": "https://fevir.net/sevco",
          "code": "SEVCO",
          "display": "research"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "https://fevir.net/sevco",
          "code": "SEVCO",
          "display": "assignment"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "https://fevir.net/sevco",
          "code": "SEVCO:01060",
          "display": "blinding of study participants"
        }
      ]
    },
    {
      "coding": [
        {
          "system": "https://fevir.net/sevco",
          "code": "SEVCO:01061",
          "display": "blinding of intervention providers"
        }
      ]
    }
  ],
  "relatesTo": [
    {
      "type": "derived-from",
      "targetCanonical": "https://clinicaltrials.gov/study/NCT02413398"
    },
    {
      "type": "derived-from",
      "targetMarkdown": "Fioretto"
    }
  ],
  "associatedParty": [
    {
      "name": "AstraZeneca",
      "role": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/research-study-party-role",
            "code": "sponsor",
            "display": "sponsor"
          }
        ]
      },
      "classifier": [
        {
          "coding": [
            {
              "system": "http://hl7.org/fhir/research-study-party-organization-type",
              "code": "industry",
              "display": "Industry"
            }
          ]
        }
      ]
    },
    {
      "name": "National",
      "role": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/research-study-party-role",
            "code": "funding",
            "display": "funding"
          }
        ]
      },
      "classifier": [
        {
          "coding": [
            {
              "system": "http://hl7.org/fhir/research-study-party-organization-type",
              "code": "government",
              "display": "Government"
            }
          ]
        }
      ]
    }
  ],
  "comparisonGroup": [
    {
      "name": "dapagliflozin",
      "type": {
        "coding": [
          {
            "system": "https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-ArmGroupType",
            "code": "EXPERIMENTAL",
            "display": "Experimental"
          }
        ]
      },
      "description": "A",
      "intendedExposure": [
        {
          "reference": "AAA",
          "type": "EvidenceVariable",
          "display": "Drug"
        }
      ],
      "observedGroup": [
        {
          "reference": "AAA",
          "type": "Group",
          "display": "Drug"
        }
      ]
    },
    {
      "name": "placebo",
      "type": {
        "coding": [
          {
            "system": "https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-ArmGroupType",
            "code": "PLACEBO",
            "display": "placebo"
          }
        ]
      },
      "description": "A",
      "intendedExposure": [
        {
          "reference": "AAA",
          "type": "EvidenceVariable",
          "display": "Drug"
        }
      ],
      "observedGroup": [
        {
          "reference": "AAA",
          "type": "Group",
          "display": "Drug"
        }
      ]
    }
  ],
  "outcomeMeasure": [
    {
      "name": "Primary",
      "type": [
        {
          "coding": [
            {
              "system": "http://hl7.org/fhir/research-study-objective-type",
              "code": "primary",
              "display": "Primary"
            }
          ]
        }
      ],
      "description": "abcd",
      "reference": {
        "reference": "Group/346162",
        "type": "Group",
        "display": "mean"
      }
    }
  ],
  "result": [
    {
      "reference": "Composition/346164",
      "type": "Composition",
      "display": "BaselineMeasureReport"
    },
    {
      "reference": "Evidence/346176",
      "type": "Evidence",
      "display": "InterventionGroupEvidence"
    },
    {
      "reference": "Evidence/346177",
      "type": "Evidence",
      "display": "ComparatorGroupEvidence: mean change from baseline in HbA1c at Week 24 in DERIVE study"
    },
    {
      "reference": "Evidence/346178",
      "type": "Evidence",
      "display": "ComparativeEvidence: mean change from baseline in HbA1c at Week 24 in DERIVE study"
    },
    {
      "reference": "Evidence/346179",
      "type": "Evidence",
      "display": "InterventionGroupEvidence: the proportion of patients achieving HbA1c <7% at 24 weeks in DERIVE study"
    },
    {
      "reference": "Evidence/346180",
      "type": "Evidence",
      "display": "ComparatorGroupEvidence: the proportion of patients achieving HbA1c <7% at 24 weeks in DERIVE study"
    },
    {
      "reference": "Evidence/346181",
      "type": "Evidence",
      "display": "ComparativeEvidence: the proportion of patients achieving HbA1c <7% at 24 weeks in DERIVE study"
    }
  ],
  "extension": [
    {
      "extension": [
        {
          "url": "type",
          "valueCode": "derived-from"
        },
        {
          "url": "quotation",
          "valueMarkdown": "quote the article text where the information was extracted"
        },
        {
          "url": "targetUri",
          "valueUri": "https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.13413"
        }
      ],
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to-with-quotation"
    }
  ]
}